Skip to content

Travoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Idose Tr, Izba, Travatan and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Travoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Travoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Changing to TRAVATAN® From Prior Therapy

    NCT01493427 · start 2011-12

    Registered record
    Registry ID
    NCT01493427
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-02
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%
    PhasePhase 4
    Registry statusCompleted
  • Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

    NCT01547598 · start 2011-12

    Registered record
    Registry ID
    NCT01547598
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    travoprost ophthalmic solution 0.004%; travoprost 0.004% / timolol 0.5% combination ophthalmic solution; Bimatoprost ophthalmic solution 0.01%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-07
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    Interventiontravoprost ophthalmic solution 0.004%; travoprost 0.004% / timolol 0.5% combination ophthalmic solution; Bimatoprost ophthalmic solution 0.01%
    PhasePhase 4
    Registry statusCompleted
  • Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

    NCT01464424 · start 2011-10

    Registered record
    Registry ID
    NCT01464424
    Conditions
    Glaucoma; Ocular Hypertension; Open-Angle Glaucoma
    Interventions
    Travoprost 0.004% ophthalmic solution; Bimatoprost 0.01% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-06
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension; Open-Angle Glaucoma
    InterventionTravoprost 0.004% ophthalmic solution; Bimatoprost 0.01% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted
  • Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

    NCT01444040 · start 2011-09

    Registered record
    Registry ID
    NCT01444040
    Conditions
    Open-angle Glaucoma
    Interventions
    iStent inject; Travoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2019-03-28
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma
    InterventioniStent inject; Travoprost
    PhasePhase 4
    Registry statusCompleted
  • Effects of Anti-Glaucoma Medications on the Ocular Surface

    NCT01315574 · start 2011-02

    Registered record
    Registry ID
    NCT01315574
    Conditions
    Glaucoma
    Interventions
    Travoprost; Latanoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2013-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTravoprost; Latanoprost
    PhasePhase 4
    Registry statusTerminated
  • Bimatoprost/Timolol Versus Travoprost/Timolol

    NCT01542710 · start 2011-01

    Registered record
    Registry ID
    NCT01542710
    Conditions
    Glaucoma
    Interventions
    Ganfort; Duotrav
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionGanfort; Duotrav
    PhaseNot applicable
    Registry statusCompleted
  • A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

    NCT01168414 · start 2010-08

    Registered record
    Registry ID
    NCT01168414
    Conditions
    Ocular Hypertension; Primary Open Angle Glaucoma
    Interventions
    Ganfort; Duotrav
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Primary Open Angle Glaucoma
    InterventionGanfort; Duotrav
    PhasePhase 3
    Registry statusCompleted
  • Travoprost Five Day Posology Study

    NCT01114893 · start 2010-04

    Registered record
    Registry ID
    NCT01114893
    Conditions
    Open-angle Glaucoma (OAG); Ocular Hypertension
    Interventions
    Travoprost 0.004%; Travoprost Vehicle; Travoprost (Groups A, B and C)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma (OAG); Ocular Hypertension
    InterventionTravoprost 0.004%; Travoprost Vehicle; Travoprost (Groups A, B and C)
    PhasePhase 2
    Registry statusCompleted
  • Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma

    NCT01004900 · start 2009-06

    Registered record
    Registry ID
    NCT01004900
    Conditions
    Glaucoma
    Interventions
    Selective Laser Trabeculoplasty; Travoprost/ Timolol/ Azopt/ Brimonidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2011-03
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionSelective Laser Trabeculoplasty; Travoprost/ Timolol/ Azopt/ Brimonidine
    PhasePhase 3
    Registry statusUnknown
  • Efficacy Study of Travoprost APS Versus TRAVATAN

    NCT00848536 · start 2009-03

    Registered record
    Registry ID
    NCT00848536
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution; Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-01
    Enrolment
    371

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution; Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
    PhasePhase 3
    Registry statusCompleted
  • Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

    NCT00767494 · start 2008-10

    Registered record
    Registry ID
    NCT00767494
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    Travoprost/Brinzolamide fixed combination; Azopt; Travatan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2009-02
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    InterventionTravoprost/Brinzolamide fixed combination; Azopt; Travatan
    PhasePhase 3
    Registry statusTerminated
  • Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

    NCT02136589 · start 2008-09

    Registered record
    Registry ID
    NCT02136589
    Conditions
    Hyperemia; Intraocular Pressure
    Interventions
    dicrofenac and travoprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperemia; Intraocular Pressure
    Interventiondicrofenac and travoprost
    PhasePhase 4
    Registry statusCompleted
  • Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT00690794 · start 2008-07

    Registered record
    Registry ID
    NCT00690794
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-05
    Enrolment
    726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®)
    PhasePhase 3
    Registry statusCompleted
  • Safety and Efficacy of Travoprost/Timolol BAC-free

    NCT00760539 · start 2008-06

    Registered record
    Registry ID
    NCT00760539
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution; Travoprost 0.004%/Timolol 0.5% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-12
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution; Travoprost 0.004%/Timolol 0.5% ophthalmic solution
    PhasePhase 3
    Registry statusCompleted
  • Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

    NCT00803387 · start 2008-04

    Registered record
    Registry ID
    NCT00803387
    Conditions
    Ocular Dryness; Ocular Irritation; Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Travaprost without BAC (Travatan Z)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-04
    Completion
    2008-09
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Dryness; Ocular Irritation; Open-Angle Glaucoma; Ocular Hypertension
    InterventionTravaprost without BAC (Travatan Z)
    PhaseNot recorded
    Registry statusCompleted